IRIS
MARRONE, Aldo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.065
EU - Europa 4.227
AS - Asia 2.223
SA - Sud America 280
AF - Africa 22
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 1
Totale 11.824
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.017
IE - Irlanda 1.363
SG - Singapore 822
UA - Ucraina 691
HK - Hong Kong 616
GB - Regno Unito 564
IT - Italia 547
CN - Cina 501
DE - Germania 365
BR - Brasile 253
SE - Svezia 237
TR - Turchia 185
FI - Finlandia 178
GR - Grecia 127
FR - Francia 60
CA - Canada 32
KR - Corea 32
BE - Belgio 25
IN - India 17
NL - Olanda 15
CZ - Repubblica Ceca 12
RU - Federazione Russa 12
AT - Austria 11
AR - Argentina 10
MX - Messico 9
IR - Iran 8
ID - Indonesia 7
BD - Bangladesh 6
EG - Egitto 6
EU - Europa 6
MA - Marocco 5
PE - Perù 5
RO - Romania 5
IQ - Iraq 4
JP - Giappone 4
ZA - Sudafrica 4
CH - Svizzera 3
CL - Cile 3
CO - Colombia 3
HN - Honduras 3
HR - Croazia 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
BG - Bulgaria 2
EC - Ecuador 2
JM - Giamaica 2
LT - Lituania 2
PA - Panama 2
PK - Pakistan 2
PS - Palestinian Territory 2
TN - Tunisia 2
TW - Taiwan 2
UG - Uganda 2
VE - Venezuela 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BN - Brunei Darussalam 1
BW - Botswana 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
HU - Ungheria 1
IL - Israele 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PL - Polonia 1
PY - Paraguay 1
UY - Uruguay 1
Totale 11.824
Salva come PNG Salva come JPEG
Città #
Dublin 1.357
Jacksonville 1.045
Chandler 713
Santa Clara 710
Hong Kong 616
New York 256
Singapore 226
Princeton 210
Roxbury 158
Woodbridge 139
Ann Arbor 126
Boardman 121
Cambridge 116
Bremen 110
Wilmington 104
Medford 100
Caserta 64
The Dalles 62
Beijing 57
Jinan 57
San Mateo 53
Shenyang 52
Ashburn 50
Nanjing 50
Naples 46
Des Moines 43
Mountain View 41
Düsseldorf 33
Seoul 32
Zhengzhou 29
Brussels 25
Nanchang 25
Munich 22
Napoli 22
Houston 21
Los Angeles 21
Norwalk 19
Washington 19
Changsha 17
Guangzhou 17
Haikou 17
Hangzhou 17
Hebei 15
Helsinki 15
Ningbo 14
Auburn Hills 13
Lanzhou 13
Nuremberg 13
Ottawa 12
Shanghai 12
São Paulo 12
Tianjin 12
Taiyuan 11
Taizhou 11
Kunming 10
Seattle 10
Amsterdam 9
Jiaxing 9
Rio de Janeiro 9
Brasília 8
Dearborn 8
Istanbul 8
Marano Di Napoli 8
London 7
Rome 7
Toronto 7
Belo Horizonte 6
Falkenstein 6
Milan 6
Aversa 5
Guastalla 5
La Prairie 5
Marigliano 5
Portici 5
Redwood City 5
Rossano 5
Zanjan 5
Andover 4
Atlanta 4
Cesa 4
Changchun 4
Contagem 4
Hefei 4
Hyderabad 4
Lappeenranta 4
Padova 4
Sacramento 4
Salvador 4
Venice 4
Vienna 4
Avellino 3
Brno 3
Buenos Aires 3
Elora 3
Erbil 3
Franca 3
Frankfurt am Main 3
Frattamaggiore 3
Fuzhou 3
Juiz de Fora 3
Totale 7.411
Salva come PNG Salva come JPEG
Nome #
Cannabinoid receptor 2-63 QQ varianti s associated with severe necroinflammation in chronic epatiti C 124
Mechanisms and clinical behavior of hepatocellular carcinoma in HBV and HCV infection and alcoholic and non-alcoholic fatty liver disease 112
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 100
Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration 99
Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C 95
Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms 92
Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: Effects of hepatitis B virus co-infection and interferon treatment 87
Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. 84
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe. 84
Activity of aminoglycosides against phagocytosed bacteria 83
Effect of prednisone priming followed by alpha-interferon in treatment of children with chronic hepatitis B: an interim analysis of a controlled trial 79
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. 78
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 78
IMPACT OF TYPE II DIABETES ON HCC APPEARANCE IN PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 78
Cannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis C 77
The impact of the CB2-63 polymorphism on the histological presentation of chronic hepatitis B. 77
PNPLA3 l148M variant as a risk factor for carotid atherosclerosis in chronic epatiti C 77
Cannabinoid Receptor 2 (CB2) Q63 variant in chronic hepatitis C: an association with a more severe hepatocellular necrosis. 74
Esperienza con l'interferone linfoblastoide nelle epatiti croniche virali 74
Le complicanze infettive in pazienti sottoposti a trapianto di cuore: dati del centro napoletano. 72
Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2a-interferon: a controlled, randomized study 71
Chronic HCV infection and neurological and psychiatric disorders: an overview. 71
Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B 71
Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon 70
Cannabinoid receptor 2 (CB2) Q63 variant is associated with a severe histological activity index in patients with chronic hepatitis C 70
Ricerca del sangue occulto nelle feci con Hemoquant: prevenzione e diagnostica. 70
Espressione dell'infezione da citomegalovirus (CMV) in pazienti cardiotrapiantati 70
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 69
Different serological, molecular and cytokine profiles characterize active and inactive disease in patients with chronic hepatitis B virus (HBV) infection 69
Long term effect of interferon (IFN) treatment of chronic hepatitis B (CHB) in pediatric patients cured of oncologic diseases 69
Hepatic steatosis and necro-inflammatory activity overestimated liver stiffness by transient elastography in staging liver fibrosis in chronic hepatitis C 69
Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection 68
Pleurite da Listeria monocytogenes in un paziente con cirrosi epatica: osservazione di un caso clinico 68
Ruolo patogenetico dell'adiponectina nella steatosi associata ad epatite C 68
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B. 68
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study 68
Absence of hepatitis C viral infection among patients with primary Sjogren's syndrome 67
Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection 67
Viral Hepatitis C 67
Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic—Standardized National Screening or One Tailored to Local Epidemiology? 66
Interferon-induced anti-HBE seroconversion correlates with a Th1 cytokine shift following emergence of core promoter mutations in chronic hepatitis B 66
Treatment of chronic hepatitis B in children with prednisone followed by alpha-interferon: a controlled randomized study 66
Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission 66
Treatment of chronic hepatitis B: efficacy of current drugs and prospects for the future 66
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe 66
Chronic hepatitis B infection in pediatric patients cured of oncologic diseases: natural history and effect of interferon treatment 66
Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C 65
Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients 65
Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. 65
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B 65
Le infezioni respiratorie da Branhamella catarrhalis in pazienti sottoposti a trapianto di cuore. 65
Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B 65
CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. 65
Hepatitis C virus infection in Italy: a multicentric sero-epidemiological study. (A report from the HCV study group of the Italian Association for the study of the liver) 64
Le infezioni delle basse vie urinarie: eziologia e suscettibilità agli antibiotici. Nostra esperienza negli ultimi 4 anni. 64
Complicanze infettive in pazienti sottoposti a trapianto di cuore. 64
Chronic HCV infection is a risk factor of ischemic stroke 64
Effects of long-term alfa interferon treatment in 344 patients with chronic hepatitis C: retrospective analysis of dosage and type of interferon used 63
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. 63
COVID-19 and arrhythmia: The factors associated and the role of myocardial electrical impulse propagation. An observational study based on cardiac telemetric monitoring 62
Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. 62
La epatite cronica da HCV con steatosi si associa ad elevato rischio aterosclerotico. 62
Interferon plus lamivudine treatment in young patients with chronic active B and C hepatitis 62
Ruolo patogenetico dell’adiponectina nella steatosi associata ad epatite C 62
Eighteen months lamivudine prophylaxis of occult HBV infection (OBI) reactivation and standard therapy of overt chronic infection in oncohematologic immunosuppressed patients: an interim analysis 62
EFFICACIA DEL TRATTAMENTO CON INTERFERONE RICOMBINANTE E LINFOBLASTOIDE IN PAZIENTI CON EPATITE CRONICA DA HCV 62
ESPERIENZA CON L'INTERFERONE LINFOBLASTOIDE NELLE EPATITI CRONICHE VIRALI 62
Correlation of serum HBeAg levels and double A1762T/G1764A HBV core promoter mutation with response to interferon in patients with chronic hepatitis B 62
Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy 62
Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis 61
Immunocompromised patients with HBsAg a determinant mutants: comparison of HBsAg diagnostic assays 61
Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection 61
SEQUENTIAL ANALYSIS OF HEPATITIS B VIRUS CORE PROMOTER AND PRECORE REGIONS IN CANCER SURVIVOR PATIENTS WITH CHRONIC HEPATITIS B BEFORE, DURING AND AFTER INTERFERON TREATMENT 61
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 61
Severe diarrhea occurring during alpha-interferon treatment for chronic hepatitis C is associated with serologic markers of celiac disease 61
Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. 61
Clinical application of lung ultrasound score on COVID-19 setting: a regional experience in Southern Italy 60
Prediction of SARS-CoV-2-Related Lung Inflammation Spreading by V:ERITAS (Vanvitelli Early Recognition of Inflamed Thoracic Areas Spreading) 60
Non-invasive respiratory support in SARS-CoV-2 related acute respiratory distress syndrome: when is it most appropriate to start treatment? 59
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 59
Hepatitis B virus DNA quantitation and detection of core promoter, precore and polymerase mutations in chronic hepatitis B: evaluation and clinical usefulness of three new commercial assays 59
Treatment of chronic hepatitis B in children with prednisone followed by alfa-interferon: a controlled randomized study 59
HCV-related steatosis and risk of atherosclerosis 59
Studio prospettico controllato del trattamento prednisone interferone in pazienti pediatrici con epatite cronica da HBV 59
Treatment of HBeAg-negative chronic hepatitis B with the ‘de novo’ combination of lamivudine and adefovir (THECLA): interim analysis of a prospective, multicenter study 59
Efficacia del trattamento con interferone ricombinante e linfoblastoide in pazienti con epatite cronica da HCV. 59
Predictors of in-hospital mortality of COVID-19 patients and the role of telemetry in an internal medicine ward during the third phase of the pandemic 59
Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection 58
The significance of hepatitis G virus in serum of patients with sporadic fulminant and subfulminant hepatitis of unknown etiology 58
Tm6sf2 e167k variant is associated with severe steatosis in chronic hepatitis c, regardless of pnapl3 polymorphism 58
Baseline HBV-DNA level is an important predictor of response to interferon in children with chronic hepatitis B 58
Studio dellla suscettibilità antibiotica di stafilococchi responsabili di infezioni nosocomiali 58
Suscettibilità antibiotica di enterococchi recentemente isolati. 58
Atherosclerosis and chronic hepatitis C virus (HCV) infection: Role of liver steatosis 58
Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct‐acting antivirals 58
Efficacy and safety of leukocite-derived alpha-interferon in the treatment of chronic hepatitis C: a prospective controlled study. 57
Infezioni respiratorie da Branhamella Catarralis in pazienti sottoposti a trapianto di cuore 57
Risk factors for carotid atherosclerosis in chronic hepatitis C: no role of the APOC3 variant 57
Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of COVID-19 patients requiring supplemental O2 therapy: a prospective controlled non-randomized study 57
Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia 56
Totale 6.779
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.710
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.710
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202074 0 0 0 0 0 0 0 0 0 0 62 12
2020/20211.682 120 15 173 95 435 16 205 159 8 214 175 67
2021/20221.284 59 3 8 15 435 14 11 35 64 124 102 414
2022/20232.682 235 45 38 216 326 221 4 174 1.276 27 64 56
2023/20241.207 95 33 61 97 372 262 17 34 4 14 77 141
2024/20252.636 27 42 33 87 502 357 391 274 436 487 0 0
Totale 12.218